

Masamichi Sugimoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/350083/publications.pdf>

Version: 2024-02-01

5
papers

134
citations

1937685

4
h-index

2272923

4
g-index

5
all docs

5
docs citations

5
times ranked

254
citing authors

#	ARTICLE	IF	CITATIONS
1	Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. <i>International Journal of Oncology</i> , 2017, 51, 425-434.	3.3	68
2	Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. <i>Anticancer Research</i> , 2019, 39, 1749-1760.	1.1	30
3	Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 199-207.	3.3	24
4	Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes. <i>Journal of Immunology</i> , 2021, 206, 1204-1214.	0.8	12
5	PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 335-344.	3.3	0